{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:57Z","timestamp":1794047457222,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284173","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:01Z","timestamp":1701315601000},"page":"1593-1597","source":"Crossref","is-referenced-by-count":2,"title":["Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age"],"prefix":"10.3324","volume":"109","author":[{"given":"Yuka","family":"Uesugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"61007","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022; 40(29):3406-3418.","DOI":"10.1200\/JCO.22.02228"},{"key":"61008","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S. Revised International Staging System for Multiple Myeloma: a Report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"61009","doi-asserted-by":"crossref","unstructured":"Phekoo KJ, Schey SA, Richards MA. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 2004; 127(3):299-304.","DOI":"10.1111\/j.1365-2141.2004.05207.x"},{"key":"61010","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bj\u00f6rkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007; 25(15):1993-1999.","DOI":"10.1200\/JCO.2006.09.0100"},{"key":"61011","doi-asserted-by":"crossref","unstructured":"Rosko A, Giralt S, Mateos M-V, Dispenzieri A. Myeloma in elderly patients: when less is more and more is more. Am Soc Clin Oncol Educ Book. 2017; 37:575-585.","DOI":"10.1200\/EDBK_175171"},{"key":"61012","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022; 36(4):1066-1077.","DOI":"10.1038\/s41375-021-01488-8"},{"key":"61013","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021; 21(11):785-798.","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"61014","doi-asserted-by":"crossref","unstructured":"Kim K, Lee JH, Kim JS. Clinical profiles of multiple myeloma in Asia-an Asian Myeloma Network study. Am J Hematol. 2014; 89(7):751-756.","DOI":"10.1002\/ajh.23731"},{"key":"61015","doi-asserted-by":"crossref","unstructured":"Terao T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K. Social frailty predicts worse outcomes in patients with multiple myeloma: a novelty in an old approach. EJHaem. 2020; 1(1):103-112.","DOI":"10.1002\/jha2.40"},{"key":"61016","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"},{"key":"61017","unstructured":"Schjesvold FH, Dimopoulos M-A, Delimpasi S. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022; 9(2):e98-110."},{"key":"61018","doi-asserted-by":"crossref","unstructured":"Terpos E, Mikhael J, Hajek R. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021; 11(2):40.","DOI":"10.1038\/s41408-021-00432-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284173\/76370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284173\/76955","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11367\/76370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:17Z","timestamp":1794045917000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284173","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}